Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajagopal, K. R.
Right arrow Articles by Jabbari, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajagopal, K. R.
Right arrow Articles by Jabbari, B.

Chest, Vol 90, 815-821, Copyright © 1986 by American College of Chest Physicians

ARTICLES

Effects of medroxyprogesterone acetate in obstructive sleep apnea

KR Rajagopal, PH Abbrecht and B Jabbari

We studied the effects of medroxyprogesterone acetate, a respiratory stimulant, on the incidence and duration of episodes of apnea and disordered breathing in 13 nonhypercapnic men with obstructive sleep apnea. Nocturnal polysomnography was done before and after four weeks of treatment with medroxyprogesterone acetate (60 mg/day) and one week after cessation of treatment. There were no significant (p less than 0.05) differences in the mean frequency of apneic episodes per hour of sleep before (31.3 +/- 5.7 [+/- SE]), during (26.8 +/- 6.6), or after (23.6 +/- 7.0) treatment, or in the mean number of disordered breathing episodes per hour of sleep before (19.4 +/- 5.6), during (21.4 +/- 5.8), or after (23.1 +/- 6.3) the period of treatment. Medroxyprogesterone did not alter significantly the total time of apnea or the total time for disordered breathing, expressed as percentages of total sleep time. Arterial oxygen desaturation during apnea and disordered breathing did not change with treatment. Medroxyprogesterone increased the minute ventilation and occlusion pressure responses to hypercapnia measured in the awake state; however, the results of this study demonstrate that medroxyprogesterone does not improve the breathing disorders during sleep in the nonhypercapnic patient with obstructive sleep apnea.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
T. Saaresranta, P. Polo-Kantola, E. Rauhala, and O. Polo
Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep
Eur. Respir. J., December 1, 2001; 18(6): 989 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. O'CONNOR, K. S. THORNLEY, and P. J. HANLY
Gender Differences in the Polysomnographic Features of Obstructive Sleep Apnea
Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1465 - 1472.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. W. HUDGEL and S. THANAKITCHARU
Pharmacologic Treatment of Sleep-disordered Breathing
Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 691 - 699.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. M. Popovic and D. P. White
Upper airway muscle activity in normal women: influence of hormonal status
J Appl Physiol, March 1, 1998; 84(3): 1055 - 1062.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American College of Chest Physicians.